Document Detail


Leveraging SBDD in Protein Therapeutic Development: Antibody Engineering.
MedLine Citation:
PMID:  22222459     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Antibodies make up the largest, growing segment of protein therapeutics in the pharmaceutical and biotechnology industries. The development or engineering of therapeutic antibodies is based to a large extent on our knowledge of antibody structure and requires sophisticated methods that continue to evolve. In this chapter, after a review of what is known about the structure and functional properties of antibodies, the current, state-of-the-art antibody engineering methods are described. These methods include antibody humanization, antigen-affinity optimization, Fc engineering for modulated effector function and extended half-life, and engineering for improved stability and biophysical properties. X-ray crystallographic structures of antibody fragments and their complexes can play a critical role in guiding and, in some cases, accelerating these processes. These approaches represent guidelines for developing antibody therapeutics with the desired affinity, effector function, and biophysical properties.
Authors:
Gary L Gilliland; Jinquan Luo; Omid Vafa; Juan Carlos Almagro
Related Documents :
20073129 - Monoclonal antibodies and progressive multifocal leukoencephalopathy.
22907369 - Affinity maturation by semi-rational approaches.
24481619 - Analysis of individual mitochondria via fluorescent immunolabeling with anti-tom22 anti...
2491429 - Laboratory screening of monoclonal gammopathies: incidence of serum monoclonal immunogl...
6208899 - A monoclonal antibody to a unique cell surface growth regulatory glycopeptide.
3621559 - Monoclonal and polyclonal antibodies compared for radioimmunoassay of somatomedin-c in ...
2793399 - Persistent hiv-2 infection of rhesus macaque, baboon, and mangabeys.
7868249 - Secretion of human interleukin 2 by recombinant mycobacterium bovis bcg.
7502829 - Induction of specific immunity at mucosal surfaces: prospects for vaccine development.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Methods in molecular biology (Clifton, N.J.)     Volume:  841     ISSN:  1940-6029     ISO Abbreviation:  Methods Mol. Biol.     Publication Date:  2012  
Date Detail:
Created Date:  2012-01-06     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9214969     Medline TA:  Methods Mol Biol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  321-49     Citation Subset:  IM    
Affiliation:
Centocor R&D Inc., Radnor, PA, USA, ggillila@its.jnj.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Application of SBDD to the Discovery of New Antibacterial Drugs.
Next Document:  A medicinal chemistry perspective on structure-based drug design and development.